The biotechnology firm, CytoDyn Inc., announced on Thursday that it has submitted a revised HIV clinical trial protocol to the FDA. This move aims to lift the current clinical hold. Simultaneously, the firm has also begun a pre-clinical study for Glioblastoma.
CytoDyn conveyed that it's initiating a research project in partnership with Albert Einstein College of Medicine and Montefiore Medical Centre. The focus of their study is on the use of leronlimab in treating Glioblastoma, a prevalent and frequently untreatable form of primary brain cancer.
On Wednesday, CytoDyn's stocks appreciated by 0.23 percent, closing at $0.17 on the Other OTC market.
